Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 20 2024 - 4:00PM
Business Wire
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company
reimagining cell therapy through the development of innovative
immunotherapies for patients with cancer and other incurable
diseases, today announced that management will participate in a
fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy
Virtual Conference on Tuesday, March 26, at 1:00 p.m. ET.
A live webcast of this discussion will be accessible from
Arcellx's website at www.arcellx.com in the Investors section. A
replay of the webcast will be archived and available for 30 days
following the event.
About Arcellx, Inc. Arcellx, Inc. is a clinical-stage
biotechnology company reimagining cell therapy by engineering
innovative immunotherapies for patients with cancer and other
incurable diseases. Arcellx believes that cell therapies are one of
the forward pillars of medicine and Arcellx's mission is to advance
humanity by developing cell therapies that are safer, more
effective, and more broadly accessible. Arcellx's lead product
candidate, anito-cel (formerly CART-ddBCMA), is being developed for
the treatment of relapsed or refractory multiple myeloma (rrMM) in
a Phase 2 pivotal trial. Anito-cel has been granted Fast Track,
Orphan Drug, and Regenerative Medicine Advanced Therapy
designations by the U.S. Food and Drug Administration.
Arcellx is also developing its dosable and controllable CAR T
therapy, ARC-SparX, through two Phase 1 programs, ACLX-001 for rrMM
and ACLX-002 in relapsed or refractory acute myeloid leukemia and
high-risk myelodysplastic syndrome. For more information on
Arcellx, please visit www.arcellx.com. Follow Arcellx on X
(Twitter) at @arcellx and LinkedIn.
Forward-looking Statements This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. All statements in this
press release that are not purely historical are forward-looking
statements, including Arcellx's expectations regarding the timing
and outcomes of clinical trials for its product candidates and the
potential impact of its product candidates and platforms on
patients and cell therapy. The forward-looking statements contained
herein are based upon Arcellx's current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. These forward-looking statements are neither promises
nor guarantees and are subject to a variety of risks and
uncertainties, including risks that may be found in the section
entitled “Part I, Item 1A (Risk Factors) in the Annual Report on
Form 10-K for the fiscal year ended December 31, 2023, filed with
the Securities and Exchange Commission (SEC) on February 28, 2024,
and other documents that Arcellx files from time to time with the
SEC. These forward-looking statements are made as of the date of
this press release, and Arcellx assumes no obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240319257163/en/
Investors: Myesha Lacy ir@arcellx.com 510-418-2412
Media: Andrea Cohen Sam Brown Inc.
andreacohen@sambrown.com 917-209-7163
Arcellx (NASDAQ:ACLX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Arcellx (NASDAQ:ACLX)
Historical Stock Chart
From Jul 2023 to Jul 2024